Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises
a combination of surgery and chemotherapy, but patients typically experience disease …

The platinum compounds cisplatin and carboplatin are widely used in the treatment of a
number of solid malignancies. Although some platinum-sensitive tumours may be cured by …

Purpose: In randomized trials the combination of cisplatin and paclitaxel was superior to
cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in …

PURPOSE: To compare the progression-free and overall survival in small-volume residual
ovarian cancer after treatment with intravenous (IV) cisplatin and paclitaxel or an …

PURPOSE: To assess progression-free survival (PFS) and overall survival (OS) in patients
with suboptimally debulked epithelial ovarian cancer receiving cisplatin (100 mg/m2) or 24 …

Background Platinum-based chemotherapy is the cornerstone of modern treatment for
ovarian, testicular, and other cancers, but few investigations have quantified the late …

Background Introduced into clinical usage in 1992 as a platinum analogue with a
distinctively different toxicity profile from cisplatin, carboplatin has become a commonly …

Treatment of ovarian cancer remains challenging despite the high complete response rate
seen after maximal surgical debulking surgery and platinum-combination chemotherapy. as …

Ovarian cancer leads to more deaths than any other gynaecological cancer in the more
developed countries. During the past 30 years, survival has increased owing to …

Epithelial ovarian cancer is the most lethal gynaecological cancer among women
worldwide, with 6000 new cases diagnosed in the UK each year. Most women present with …